Literature DB >> 1682924

Construction of intertypic chimeric dengue viruses by substitution of structural protein genes.

M Bray1, C J Lai.   

Abstract

Dengue virus contains an 11-kilobase positive-strand RNA genome that codes for, in one open reading frame, three structural proteins (capsid, premembrane, and envelope), followed by seven nonstructural proteins. The structural protein genes of a full-length cDNA clone of type 4 dengue virus were replaced with the corresponding genes of dengue 1 or dengue 2 to create intertypic chimeric cDNA. The RNA transcripts made from these templates were infectious when transfected into permissive cells in culture. Progeny of chimeric cDNA produced apparently authentic dengue 1 or dengue 2 structural proteins, together with dengue 4 nonstructural proteins, and as a consequence exhibited type 1 or type 2 serological specificity. Both of the chimeras ultimately grew to the same titer as their type 1 or type 2 parent, but the type 2/type 4 chimera grew very slowly. This chimera also produced small plaques; in contrast, the type 1/type 4 chimera produced normal size plaques. The type 2/type 4 chimera retained the mouse neurovirulence of the dengue 2 virus, which was the source of its structural protein genes. Each of the mice inoculated intracerebrally with the chimera died, but survival time was prolonged. The retardation of replication of the type 2/type 4 chimeric virus suggests that this virus and possibly other intertypic dengue virus chimeras with similar properties should be examined for attenuation in primates and possible usefulness in a live dengue virus vaccine for humans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1682924      PMCID: PMC52924          DOI: 10.1073/pnas.88.22.10342

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Recent advances in our knowledge of dengue and sandfly fever.

Authors:  A B SABIN
Journal:  Am J Trop Med Hyg       Date:  1955-03       Impact factor: 2.345

2.  Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses.

Authors:  W R DORRANCE; J W FRANKEL; I GORDON; P R PATTERSON; R W SCHLESINGER; J W WINTER
Journal:  J Immunol       Date:  1956-11       Impact factor: 5.422

3.  Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins.

Authors:  B Falgout; M Pethel; Y M Zhang; C J Lai
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

4.  Research on dengue during World War II.

Authors:  A B SABIN
Journal:  Am J Trop Med Hyg       Date:  1952-01       Impact factor: 2.345

5.  Complete nucleotide sequence of dengue type 3 virus genome RNA.

Authors:  K Osatomi; H Sumiyoshi
Journal:  Virology       Date:  1990-06       Impact factor: 3.616

6.  Sequence of the dengue-1 virus genome in the region encoding the three structural proteins and the major nonstructural protein NS1.

Authors:  P W Mason; P C McAda; T L Mason; M J Fournier
Journal:  Virology       Date:  1987-11       Impact factor: 3.616

7.  Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies.

Authors:  M K Gentry; E A Henchal; J M McCown; W E Brandt; J M Dalrymple
Journal:  Am J Trop Med Hyg       Date:  1982-05       Impact factor: 2.345

8.  Virulence and immunogenicity of a temperature-sensitive dengue-2 virus in lower primates.

Authors:  V R Harrison; K H Eckels; J W Sagartz; P K Russell
Journal:  Infect Immun       Date:  1977-10       Impact factor: 3.441

9.  Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans.

Authors:  C H Hoke; F J Malinoski; K H Eckels; R M Scott; D R Dubois; P L Summers; T Simms; J Burrous; S E Hasty; W H Bancroft
Journal:  Am J Trop Med Hyg       Date:  1990-08       Impact factor: 2.345

10.  Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers.

Authors:  K T McKee; W H Bancroft; K H Eckels; R R Redfield; P L Summers; P K Russell
Journal:  Am J Trop Med Hyg       Date:  1987-03       Impact factor: 2.345

View more
  42 in total

1.  Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response.

Authors:  R G van Der Most; K Murali-Krishna; R Ahmed; J H Strauss
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses.

Authors:  A G Pletnev; M Bray; J Huggins; C J Lai
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

3.  Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.

Authors:  S Butrapet; C Y Huang; D J Pierro; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.

Authors:  C Y Huang; S Butrapet; D J Pierro; G J Chang; A R Hunt; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

5.  Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence.

Authors:  Alexander J McAuley; Maricela Torres; Jessica A Plante; Claire Y-H Huang; Dennis A Bente; David W C Beasley
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

6.  Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys.

Authors:  Joseph E Blaney; James Speicher; Christopher T Hanson; Neeraj S Sathe; Stephen S Whitehead; Brian R Murphy; Alexander G Pletnev
Journal:  Vaccine       Date:  2008-06-13       Impact factor: 3.641

7.  Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge.

Authors:  M Bray; R Men; C J Lai
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

8.  Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4.

Authors:  A G Pletnev; R Men
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

Review 9.  The yellow fever 17D virus as a platform for new live attenuated vaccines.

Authors:  Myrna C Bonaldo; Patrícia C Sequeira; Ricardo Galler
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

10.  Completion of Kunjin virus RNA sequence and recovery of an infectious RNA transcribed from stably cloned full-length cDNA.

Authors:  A A Khromykh; E G Westaway
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.